ShareValue scores for COO: Valuation 46, Quality 21, Growth 39, Health 17.

COO
NASDAQ

The Cooper Companies, Inc

$73.32(-2.03%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

1% to 17%
Valuation
46
Fair Value
Price vs Value
Quality
21
Weak
Business Strength
Growth
39
Weak
Revenue & Earnings
Health
17
Stressed
Financial Stability
Momentum
34
Bearish
Price Trend

Company Details

About

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026